Analyst Recommendation Trends
Wall Street analyst consensus for QTTB over the last few months:
Latest QTTB News
This Biotech Had Good News for Hair Loss Sufferers. So Why Is the Stock Sinking?
Nektar Therapeutics reports sustained hair regrowth after treatment ended, while analysts see positive implications for a competing drug.
Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026
Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical-stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced additional 36-week results and initial findings from the 16-week off-drug period from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe AA. These results were presented across a late-breaking oral and poster presentation at th
Q32 Bio Announces Additional 36-Week Results And Initial Findings From The 16-Week Off-Drug Period From Part B Of The SIGNAL-AA Phase 2A Clinical Trial Evaluating Bempikibart In Patients With Severe Or Very Severe AA; Clinically Meaningful Efficacy Data Observed On Primary And Key Secondary Endpoints At Week 36; Robust Durability, Including Maintenance And Deepening Of Response
These results were presented across a late-breaking oral and poster presentation at the European Academy of Dermatology and Venereology ("EADV") Congress 2026. Q32 Bio previously announced topline results from
Jefferies Initiates Coverage On Q32 Bio with Buy Rating, Announces Price Target of $29
Jefferies analyst Maury Raycroft initiates coverage on Q32 Bio (NASDAQ:QTTB) with a Buy rating and announces Price Target of $29.
Q32 Bio: Durable Hair Regrowth Remains The Goal
QTTB stock outlook: bempikibart may deliver lasting alopecia areata hair regrowth; financing reduces near-term risk.
Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026
Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical-stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced that additional 36-week results and initial findings from the 16-week off-drug period from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe AA will be featured across late-breaking oral and poster presentations at the Europea
Q32 Bio Presents Additional 36-Week Data From Its Part B Of SIGNAL-AA Phase 2a Clinical Study Of Bempikibart At European Academy Of Dermatology And Venereology Congress
Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical-stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today
Q32 Bio Inc. (QTTB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Q32 Bio Inc. (QTTB) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 11:30 AM EDTCompany ParticipantsShelia Violette - Co-founder,...
Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer
Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical-stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today announced the appointment of José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer.
Down 23.1% in 4 Weeks, Here's Why Q32 Bio (QTTB) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Q32 Bio (QTTB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
These 2 ‘Monster Growth’ Stocks Aren’t Done Climbing, Say Analysts
Ask any old-school market investor and he’ll tell you that the cliché is true, and ‘past performance cannot guarantee future returns.’ If that were true without exception, then growth investing would not be a viable option – but we all know that investors love to buy into stocks that have shown enormous growth in recent months. The ‘monster growth’ stocks are popular because investing into them is successful. The key is understanding the smart middle way, and treating stocks as individuals, with
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-25 | Violette Shelia M. | -2,798 | $16.56 | $46,335 |
| 2026-08-25 | Kalowski Lee | -3,972 | $16.56 | $65,776 |
| 2026-08-25 | Morrison Jodie Pope | -9,845 | $16.56 | $163,033 |
| 2026-07-16 | Violette Shelia M. | +37,500 | - | - |
| 2026-07-16 | Kalowski Lee | +53,250 | - | - |
| 2026-07-16 | Morrison Jodie Pope | +132,000 | - | - |
| 2026-06-30 | Manke Isaac | -53,521 | - | - |
| 2026-06-30 | Manke Isaac | +53,521 | $2.8 | $149,859 |
| 2026-06-12 | Lundberg Sven Ante | +10,826 | - | - |
| 2026-06-12 | Xu Diyong | +10,826 | - | - |
| 2026-06-12 | GRAYZEL DAVID S. | +10,826 | - | - |
| 2026-06-12 | Manke Isaac | +10,826 | - | - |
| 2026-06-12 | TZIANABOS ARTHUR | +10,826 | - | - |
| 2026-06-12 | Iwicki Mark T | +10,826 | - | - |
| 2026-06-12 | Thistle Mary | +10,826 | - | - |
| 2026-06-12 | LAPORTE KATHLEEN | +10,826 | - | - |
| 2026-06-12 | GRAYZEL DAVID S. | +9,810 | - | - |
| 2026-06-12 | Xu Diyong | +9,810 | - | - |
| 2026-06-12 | Lundberg Sven Ante | +9,810 | - | - |
| 2026-06-12 | Manke Isaac | +9,810 | - | - |
| 2026-06-12 | TZIANABOS ARTHUR | +9,810 | - | - |
| 2026-06-12 | Iwicki Mark T | +9,810 | - | - |
| 2026-06-12 | Thistle Mary | +9,810 | - | - |
| 2026-06-12 | LAPORTE KATHLEEN | +9,810 | - | - |
| 2026-05-28 | Xu Diyong | +625,000 | $8 | $5,000,000 |
| 2026-05-28 | Xu Diyong | +1,250,000 | $8 | $10,000,000 |
| 2026-05-28 | ORBIMED ADVISORS LLC | +625,000 | $8 | $5,000,000 |
| 2026-05-28 | ORBIMED ADVISORS LLC | +1,250,000 | $8 | $10,000,000 |
| 2026-02-25 | Violette Shelia M. | -2,815 | $4.5144 | $12,708 |
| 2026-02-25 | Kalowski Lee | -3,995 | $4.5144 | $18,035 |
| 2026-02-25 | Morrison Jodie Pope | -9,896 | $4.5144 | $44,675 |
| 2026-02-24 | Violette Shelia M. | +37,500 | - | - |
| 2026-02-24 | Kalowski Lee | +53,250 | - | - |
| 2026-02-24 | Morrison Jodie Pope | +132,000 | - | - |
| 2026-01-15 | GRAYZEL DAVID S. | +16,363 | $2.75 | $44,998 |
| 2026-01-15 | Lundberg Sven Ante | +20,363 | $2.75 | $55,998 |
| 2026-01-15 | LAPORTE KATHLEEN | +23,272 | $2.75 | $63,998 |
| 2025-12-02 | Kalowski Lee | -9,072 | $3.4607 | $31,395 |
| 2025-12-02 | Morrison Jodie Pope | -22,506 | $3.46 | $77,871 |
| 2025-10-23 | Lundberg Sven Ante | +53,521 | - | - |
| 2025-10-23 | Xu Diyong | +53,521 | - | - |
| 2025-10-23 | GRAYZEL DAVID S. | +53,521 | - | - |
| 2025-10-23 | Manke Isaac | +53,521 | - | - |
| 2025-10-23 | TZIANABOS ARTHUR | +53,521 | - | - |
| 2025-10-23 | Iwicki Mark T | +53,521 | - | - |
| 2025-10-23 | Thistle Mary | +53,521 | - | - |
| 2025-10-23 | LAPORTE KATHLEEN | +53,521 | - | - |